Ascendiant Capital Maintains Buy on Vivos Therapeutics, Raises Price Target to $6.6
Portfolio Pulse from Benzinga Newsdesk
Ascendiant Capital has maintained a Buy rating on Vivos Therapeutics and raised the price target from $6.4 to $6.6, indicating a positive outlook for the company's stock.
August 20, 2024 | 9:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ascendiant Capital has maintained a Buy rating on Vivos Therapeutics and increased the price target from $6.4 to $6.6, suggesting a positive short-term outlook for the stock.
The increase in the price target from $6.4 to $6.6 by Ascendiant Capital, along with the maintained Buy rating, indicates a positive sentiment from analysts. This is likely to boost investor confidence and could lead to a short-term increase in VVOS's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100